Intervention

Pioglitazone 15mg

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 4 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials4
Recruiting1
Common conditions5
Lead sponsors shown4
Advertisement

Clinical trials

4 shown
Pioglitazone Therapy Targeting Fatigue in Breast CancerNCT05013255 · 2021-12-23
RECRUITING
A Study to Evaluate the Efficacy and Safety of Pioglitazone 15mg or 30mg Add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and DapagliflozinNCT04885712 · 2021-05-28
COMPLETED
Efficacy and Safety of CKD-501 Versus Pioglitazone When Added to MetforminNCT01106131 · 2010-05-01
COMPLETED
Effect of Pioglitazone on Oxidative Load, Inflammatory End-Points and Vascular Reactivity in Obese Non-Diabetic Patients: A Dose Ranging StudyNCT01161394
COMPLETED

Trial status mix

COMPLETED3
RECRUITING1

Phase mix

PHASE32
PHASE21
PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.